BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 4.7% – Here’s Why

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded up 4.7% during trading on Monday . The company traded as high as $7.75 and last traded at $7.75. 1,648,389 shares changed hands during trading, a decline of 41% from the average session volume of 2,793,625 shares. The stock had previously closed at $7.40.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $15.00 target price on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Finally, Wedbush started coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

The company has a 50 day moving average price of $7.82 and a 200 day moving average price of $7.74. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of -12.34 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. BioCryst Pharmaceuticals’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.28 earnings per share. Research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC increased its position in shares of BioCryst Pharmaceuticals by 113.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company’s stock valued at $283,000 after purchasing an additional 20,043 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of BioCryst Pharmaceuticals by 5.2% during the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 2,146 shares during the last quarter. Pallas Capital Advisors LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $148,000. Merit Financial Group LLC purchased a new position in BioCryst Pharmaceuticals in the first quarter valued at approximately $100,000. Finally, Rhumbline Advisers grew its holdings in BioCryst Pharmaceuticals by 3.9% during the first quarter. Rhumbline Advisers now owns 321,154 shares of the biotechnology company’s stock valued at $2,409,000 after purchasing an additional 12,022 shares during the period. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.